GB Sciences Overview
GB Sciences (GBLX) has a ROE of 17.74%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow17.74%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, GBLX shows a ROE of 17.74%. That is above the Healthcare sector average of 11.15%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 11.15%. GB Sciences is at 17.74%, which is higher that average. That is roughly 59.1% above the sector mean. Use the comparison chart on this page to see how GBLX stacks up against individual peers as well.
Check the historical chart to see whether GBLX's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare GB Sciences with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has GB Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 17.74%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 11.15%, while GBLX is at 17.74%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
